ASX ANNOUNCEMENT

US PATENT FOR THE PREVENTION OR TREATMENT OF ISCHEMIA

- **Patent for the treatment of ischemia using midkine allowed in the US**
- **Patent family is critical to ischemia programs (CAMI103)**
- **European and Australian patents already granted**

SYDNEY, 14 November 2011: Cellmid Limited (ASX: CDY) Notice of Allowability has been issued by the United States Patent and Trademark Office (USPTO) for Cellmid's patent application 10/371,030, entitled "Pharmaceutical composition for preventing or treating ischemic disease" ('030). This is a key patent in Cellmid's ischemia patent family, which in turn is fundamental to the CAMI103 program for the treatment of heart attack and strengthens the company's dominant intellectual property position in the midkine (MK) space.

Patent '030 is part of the global patent family owned by Cellmid that covers the use of MK as a therapeutic agent in ischemic diseases such as stroke and heart attack. Patents in this family have already been granted in all major European jurisdictions, in Australia and in South Korea. The ischemia family patents complement and reinforce Cellmid's Horiba patent family, which gives global coverage for the use of MK in treating myocardial disorders and heart failure.

"Allowance of patent '030 in the US is a significant addition to Cellmid's IP assets, and is especially important as it provides extra patent protection around our current program in heart ischemia", said Cellmid CEO, Maria Halasz. "We also gain protection under this patent family for the use of MK for the treatment of stroke, another future product development program in Cellmid's extensive pipeline", she added.

Cellmid holds the most significant intellectual property assets related to MK worldwide. Cellmid's patent portfolio currently includes 79 patents in 21 patent families, covering the use of MK and anti-MK agents for therapeutic purposes in a number of diseases and the use of MK as a diagnostic marker in cancer and other disorders.

End

Contact:
Maria Halasz, CEO
T +612 9299 0311

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases, heart attack and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced clinical development program is for the treatment of acute myocardial infarction (AMI) utilising the midkine protein. Cellmid is also developing anti-midkine antibodies for the treatment of inflammatory and autoimmune disorders. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. Cellmid's first product, the MK-ELISA, is a blood test that sensitively and accurately measures serum midkine levels.

Midkine (MK)

Midkine is a multifunctional growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, because midkine is only present in a disease context, targeting midkine does not harm normal healthy tissues.